On August 24, 2026, a status update was recorded for the Phase 3 trial evaluating retatrutide once weekly, titled "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity" (TRIUMPH-Outcomes). The trial, registered under identifier NCT06383390, is listed with a status of active, not recruiting. This designation means the study is ongoing but is no longer enrolling new participants at this time. The trial is examining cardiovascular and kidney outcomes in adults living with obesity who are receiving retatrutide. No results, efficacy data, or safety findings were included in this update. The record reflects only the current administrative status and phase classification of the study. Further details about the trial's design, timeline, or eventual outcomes were not provided in this event. Readers interested in the compound's broader development history and regulatory context can consult the retatrutide overview for additional background.
Retatrutide Phase 3 TRIUMPH-Outcomes Trial Status Updated
See the full retatrutide overview
Source: https://clinicaltrials.gov/study/NCT06383390